Revista Clínica Española (English Edition) Revista Clínica Española (English Edition)
Rev Clin Esp 2018;218:128-32 - Vol. 218 Num.3 DOI: 10.1016/j.rceng.2017.12.005
Brief Original
Prognostic implications of telomerase expression in pituitary adenomas
Implicación pronóstica de la expresión de telomerasa en adenomas hipofisarios
F. Tortosaa,b,, , S.M. Webbb
a Servicio de Anatomía Patológica, Centro Hospitalar Lisboa Norte, EPE-Hospital de Santa Maria, Lisboa, Portugal
b Departamento de Medicina/Endocrinología, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Unidad 747, Instituto de Salud Carlos III, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Received 11 July 2017, Accepted 14 December 2017
Abstract
Objectives

To analyze the prognostic value of telomerase expression in patients with pituitary adenomas (PAs) followed-up for at least 8 years.

Patients and methods

A retrospective study was conducted of samples from 51 PAs (40 typical and 11 atypical) from patients who underwent transsphenoidal surgery between 2006 and 2008 and from 10 normal pituitary glands obtained by autopsy. Telomerase expression was assessed by immunohistochemistry, correlating the expression with that of Ki-67 and p53.

Results

We observed telomerase expression in 43 PAs (84.3%, 32 of the 40 typical PAs and in the 11 atypical PAs), which was higher in the clinically nonfunctioning cases (p=0.0034) and very rare in the patients with acromegaly (p=0.0001). There was a significant association between the percentage of tumor cells (>10%) and the recurrence of the adenoma (p=0.039). There was no correlation with the expression of Ki-67 and p53 (p=0.4986), and there were no differences according to age, sex, tumor size and invasiveness.

Conclusions

A telomerase expression rate greater than 10% in the pituitary tumor tissue was associated with recurrence or progression of the PA, especially in the nonfunctioning cases.

Resumen
Objetivos

Analizar el valor pronóstico de la expresión de telomerasa en pacientes con adenomas hipofisarios (AH) seguidos durante al menos 8 años.

Pacientes y métodos

Estudio retrospectivo de las muestras de 51 AH (40 típicos y 11 atípicos) de pacientes sometidos a cirugía transesfenoidal entre 2006 y 2008, y de 10 hipófisis normales obtenidas por autopsia. Se evaluó la expresión de telomerasa por inmunohistoquímica correlacionándola con la de Ki-67 y p53.

Resultados

Se observó expresión de telomerasa en 43 AH (84,3%, 32 de los 40 típicos y en los 11 atípicos), siendo mayor en los casos clínicamente no funcionantes (p=0,0034) y muy escasa en los pacientes con acromegalia (p=0,0001). Hubo una asociación significativa entre el porcentaje de células tumorales (>10%) y la recurrencia del adenoma (p=0,039). No hubo correlación con la expresión de Ki-67 y p53 (p=0,4986) ni se observaron diferencias en función de la edad, el sexo, el tamaño o la invasividad tumoral.

Conclusiones

Un índice de expresión de telomerasa mayor del 10% en el tejido hipofisario tumoral se asoció a recurrencia o progresión del AH, especialmente en los no funcionantes.

Keywords
Pituitary adenoma, Biomarker, Immunohistochemistry, Telomerase reverse transcriptase
Palabras clave
Adenoma hipofisario, Biomarcador, Inmunohistoquímica, Telomerasa transcriptasa inversa

Article

To access the full text of the publication Revista Clínica Española (English Edition) you need to be a subscriber or member of the Sociedad Española de Medicina Interna.

  • If you are a member of the Sociedad Española de Medicina Interna::
    1.- You must go to the following address http://www.fesemi.org/publicaciones/revista-clinica/ultimo/view
    2.- Authenticate as a member of the SEMI. You must use your login details
    3.- Access to the contents of Revista Clínica Española

  • If you are a subscriber:
    Can you recover your data in the "I Forgot my Password" button on the right sidebar of this website.

Rev Clin Esp 2018;218:128-32 - Vol. 218 Num.3 DOI: 10.1016/j.rceng.2017.12.005
Cookies Policy
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.